to epithelial cells has been shown in vitro to depend on pili but their relationship to the glycocalyx biofilm has yet to be explored. The actions of its toxins and proteases have been Pseudomonas aeruginosa is well recognised as an ocular pathogen causing severe keratitis, corneoscleritis and endophthalmitis. Keratitis may result in corneal melting and perforation.
However, Ps. aeruginosa is an opportunistic pathogen and certain factors are required for the establishment of keratitis such as trauma, the presence of pre-existing ocular disease including Herpes simplex infection, immunosuppression, an association with wearing of soft contact lenses or use of contaminated solutions and possibly genetic predisposition. Host factors are also important as polymorphonuclear cell function is primarily responsible for preventing invasion of tissue. Adults have not been reported to disseminate the infection outside the ocular tissues although this has occurred in premature infants.
Animal models have been pursued to identify initiating factors of pseudomonas keratitis. Adult rabbits, guinea pigs and mice are susceptible to develop experimental keratitis but only if corneal abrasion is performed or large numbers of bacteria are injected intra-stromally.l The mouse model has been further used to identify genetic determinants in strains susceptible and resistant to corneal infection. 2 Microscopic examination of mouse and rabbit cornea has shown necrosis of epithelial, keratocytes and endothelial cells and, in both animals and humans, degradation of collagen fibrils with extensive dissolution of the stroma.
Specific Virulence Factors
Both cell-associated and extra-cellular products of Ps. aeruginosa contribute to its virulence. 3
Surface structures include pili and the poly saccharide capsule (or glycocalyx), both involved in initial attachment to host cells. Bacterial Surface-Associated Factors:
The attachment of Ps. aeruginosa to traumatised corneal epithelial cells, but not to intact epithelium, has been studied in a mouse model by Ramphal et al4 and in the rabbit by Stern et al.5 They showed by electron microscopy that pseudomonas adhered only to the injured areas and the exposed stroma. Stern et al showed that stromal invasion occurred within one hour, when bacteria were rarely seen on the cell surface or in the epithelial defect, and that many bacteria had migrated between the basal epithelium and corneal stroma or were present intracellularly.5
We found in our rabbit model that Ps. aeruginosa disappeared from the corneal surface within four hours from inoculation with 106 bacteria, unless trauma was made with a 4 mm circular trephine into the anterior stroma. Invasion of the traumatised epithelial cells occurred after 7.5 minutes followed by bacteria present within the stroma at later intervals.6
Ps. aeruginosa has an outer membrane and cell wall composed of lipids, proteins and lipopolysaccharide from which project numerous pili (fimbriae) and a single polar flagellum. Pili have been studied for their adherence to epithelial cells of the human cornea 7 and mouth8,9 as well as mouse skin, 10
Reichert7 studied the role of pili in an in vitro adherence assay system, using a homogenous purified pilin preparation, and demonstrated adherence to corneal epithelial cells which blocked subsequent adherence by isotope labelled pilin. Paranchych et al9 found pseudomonas pili to be flexible filaments of 60 angstrom diameter and 2500nm average length. Haemolytic toxins Two haemolysins are excreted of which one, which is heat labile, is a protein of 78,000 daltons with phospholipase C activity while the other is a glycolipid that acts by a detergent-like mechanism.21 Both are produced under phosphate-limiting growth conditions. These enzymes lyse red cells of various species, all of which have membranes containing phosphatidyl choline. Mutants have been produced which lack production of phospholipase C (if cultured in the absence of phosphate) which has been mapped in the same region of the chromosome as the regulatory IOCUS. 21 Nicas and Iglewski recently compared isolates of Ps. aeruginosa from environmental (soil and water) sources and bacteraemic patients for levels of production of exotoxin A, proteases and phospholipase C activity.27 No significant differences were found demonstrating the patho genic potential of the environmental strains.
Host fa ctors:
Evidence from experimental pseudomonas keratitis has shown the importance of host factors in the elimination of bacteria28 particu larly phagocytosis by PMNs. 29 In the superficial injury model PMNs enter the wound within the first four-eight hours from the tear film followed by a substantial migration from the limbus at 48 hours28 when the tear film derived component may be of relatively little importance. 30 Phagocytosis is mandatory to the elimination of P aeruginosa. A recent study in immuno competent and naive rats has demonstrated the importance to phagocytosis of an opsonic anti body response, probably IgG mediated, to P aeruginosa together with complement com ponents. The recruitment of PMNs was independent of this response29 for which active infection with P aeruginosa, as well as bacterial products and endotoxin, are a very potent stimulus.3 o
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The potential role of PMNs in corneal necrosis has been reviewed by Jones and there is no doubt that the products of PMN degranula tion are capable of corneal necrosis. 31 Phagocytosis is associated with degranulation of PMN s and degradation of the corneal stroma and overlying epithelium.28 This may be dependent on an antibody response and has been associated with increased PMN protease activity. 29 We have already discussed evidence that suggests the importance of bacterial factors in corneal destruction.23·26 However the relative contributions of bacterial products and the results of PMN degradation to the progression of liquefactive necrosis is not certain. 32 It is possible that the bacterial factors are more important for the establishment of infection following which PMN degradation may be more important in stromal necrosis. 32 The relative role of pathogen and host response in the deve lopment of corneal necrosis may depend on the strain of P. aeruginosa.28
Therapy of Pseudomonas Keratitis

Aims
The preceding review of the pathogenesis of pseudomonas keratitis has shown how this organism produces a formidable infection33 which, if unchecked, can rapidly progress to corneoscleritis, corneal perforation, and a resulting panophthalmitis. The aims of therapy are to prevent extension of the infection, eliminate the pathogen, control inflammation and encourage healing. Effective elimination of the organism is the key to treatment of early disease. However in late disease the remaining therapeutic objectives are of equal importance and consideration must be given to the toxicity of treatment, the control of the host response and, in patients with pre-existing ocular surface disease, the improvement of the corneal environ ment. The wide variety of clinical and experi mental treatment alternatives and adjuncts to antibiotic therapy, that have been described, underlie the difficulty of achieving these aims. An understanding of the pathogenesis is vital both to the selection of current diagnostic and therapeutic measures as well as to future developments.
Diagnosis
Although P. aeruginosa is unusual amongst corneal pathogens in producing an almost pathognomonic keratitis34 early cases have no typical appearance and may present as corneal erosions35 and small single or multiple foci of corneal suppuration. For these reasons, and because of the emergence of strains of P. aeruginosa resistant to gentamicin,36 successful therapy is dependent on isolating the organism and determining its antibiotic susceptibilities. The principles, pitfalls and methods of culturing corneal ulcers and of preparing smears for immediate microscopy have been exhaustively described.34,37 We use a disposable hypodermic needle, rather than the commonly advocated Kimura spatula, to take multiple samples from the ulcer. Needles are easily available and allow samples of infected stroma to be more readily obtained from infected tissue and small lesions than the larger spatula.
Initial treatment
Our initial choice of antibiotic is made on the result of the Gram stain.38 A report of Gram negative rods is followed by treatment with half hourly topical fortified gentamicin (15 mg/ml). If there are mixed organisms or the report is nega tive or uncertain we start combined broad spectrum topical therapy with fortified genta micin and cefuroxime given alternatively every quarter or half hour; the cefuroxime is omitted as soon as the diagnosis of P. aeruginosa is con firmed. Treatment is continued day and night, usually for 3 days when, providing there are signs of clinical improvement, the frequency is reduced to hourly during the day only. The rationale for this choice of antibiotic and route of administration is discussed below.
Choice of antibiotic
An aminoglycoside remains the first choice for treatment. To bramycin has a 2-4x lower mean inhibitory concentration (MIC) than genta micin.39 However because of the very high levels of antibiotic that are achieved by topical therapy with fortified preparations, 20-80x the MIC in a rabbit model,4 o this is usually of little significance so that we have continued to use gentamicin in most cases. In addition to its bactericidal activity it has been shown that sub inhibitory concentrations of gentamicin will inhibit the production of exotoxin A and elastase as well as inhibit bacterial adhesion to HEp-2 cells;41 this may account for some of the thera-peutic effect. The emergence of aminoglycoside resistant P. aeruginosa mutants during therapy is well recognised outside the eye, usually occurring after prolonged or topical therapy or in association with a fo reign body.4246 Such mutants have been linked with temperature sen sitivity in the progenitor strains43 and have been shown to have reduced virulence properties44 although remammg capable of causing infection.45 These mutants may be showing per sistence rather than resistance to aminoglyco sides.46 Their possible occurrence in keratitis needs to be remembered particularly when infections recrudesce after prolonged treatment, a well documented event. 33 Fortunately genta micin resistant P. aeruginosa has been rare in our patients and the most frequent reason for changing to an alternative antibiotic has been the epithelial toxicity associated with topical amino glycoside therapy which is discussed below. Alternatives to the aminoglycosides are the anti pseudomonal penicillins and the extended spec trum cephalosporins. Icarcillin is less active than azlocillin but we have continued to use it because the topical preparation is stable in aqueous solution for up to 8 days (extrapolated from manufacturers information) whereas the stability of the newer penicillins is uncertain. Providing the isolate is sensitive it has been as effective and less toxic than fortified topical gentamicin. Of the extended spectrum cephalosporins ceftazidime has the most reliable anti pseudomonal activity47 and is a useful reserve antibiotic. Of the newer antibiotics, the fluoroquinolones such as norfloxacin are stable in solution and are very active against P aeruginosa. 39.48 They need to be evaluated in keratitis but resistance to them has emerged during single drug treatment of other P. aeruginosa infections.
Combined therapy of an antipseudomonal penicillin and aminoglycoside, on the grounds of synergism that occurs in vitro, is in widespread use. However the case for its use in keratitis is unsubstantiated and like others34 we consider that it adds an additional complication to topical treatment unless the infection is hospital acquired and likely to be resistant to gentamicin.
Route and dose of administration
It has been well established that intensive topical fo rtified aminoglycoside therapy in experimental keratitis will give high levels of drug in the cornea40 and eliminate P aeruginosa more effectively than the subconjunctival route in the rabbit modeJ.28.49.50 Commercially available unfortified preparations have no place in treatment. Similarly, systemic therapy has been shown to be of no value in experimental kera titis.28.49.50 Although very high corneal peak levels of antibiotic are achieved by subcon junctival administration they later fall, within 3-6 hours, to well below those obtained by hourly topical fo rtified application. It is likely that subconjunctival antibiotic reaches the cornea by leak back from the conjunctival puncture site29.49 as well as direct diffusion. 29 Because of the short duration of the effect of sub conjunctival injections, the associated pain and discomfort and the resulting conjunctival ischaemia and necrosis overlying the injection site this route, like systemic therapy, is rarely indicated. 19. 51 We use gentamicin fo rtified to 15mg/ml, rather than the commercial preparation at 3mg/ml, and the penicillins and cephalosporins in aqueous solution at 50mg/ml; the principles of manufacturing topical antibiotics have been described. 38 
Modification of antibiotic treatment after culture results are available
Treatment is changed to a single antibiotic as soon as culture results confirm the growth of P. aeruginosa and only modified, when sensi tivities are available, if the organism is resistant to the antibiotic used. This is because the in vivo effect of antibiotics may be different from the in vitro effect due to modulation by bacterial host interaction, effect of host fa ctors, such as phago cytosis and possibly the subinhibitory effects already described. However, if no apparent response occurs when the organism is not fully sensitive, combination with another antibiotic should commence.
Adjunctive therapy
Cycloplegia is the only adjunctive treatment indicated in the initial therapy of P aeruginosa keratitis.
Steroid therapy has been widely discussed in relation to P aeruginosa keratitis. Steroid suppresses PMN migration, reducing the numbers at an inflammatory site, their function, phagocytosis, intracellular digestion of phago-cytosed material and degranulation. 52 In experimental studies steroids have not· been shown to compromise effective antibiotic therapy.53,54 However combined antibiotic and steroid treatment of a resistant strain of P.
aeruginosa in an experimental model enhanced bacterial growth, compared to antibiotic alone55 and delayed healing without improvement in the degree of corneal inflammation and scarring. 56 Clinical experience has shown that steroid treatment may be associated with recurrent infection.33,57 There is little evidence that they have any part to play in the management of keratitis when the antibiotic susceptibility of the organism is unknown56 and in the early stages of disease when replicating microorganisms are present. 54 Despite their theoretical advantage in reducing the recruitment of PMNs. and consequent release of hydrolytic enzymes, there is reluctance to use them even late in P.
aeruginosa keratitis because of known bacterial persistence. Also, for consideration, is their effect on decreasing fibroblastic activity and inhibition of healing which may in themselves precipitate corneal perforation. 3 3 . 37 . 38 . 5 1 We have used steroids in only a few cases on a trial basis to control neovascularisation, which rarely starts before 10 days from onset, or in cases of late corneal melt when a trial can be indicated to test whether a reduction of PMN activity is beneficial.
Protease inhibitors such as cysteine, L-cysteine and calcium EDTA have not been found clinically useful37,38 and have been shown to have toxic effects on the corneal epithelium. 58 
Complicated cases
Deterioration of the patient who is on normally effective doses of antibiotic may be due to a number of factors which should be considered in turn. Organisms resistant to aminoglycosides are uncommon but occurred in 12 % of one series;36 routine sensitivity testing is an important guide to the management of this infection. Prolonged treatment is necessary to eliminate persistent organisms; exacerbations have followed a reduc tion in the frequency of topical treatment often when overnight medication is ceased. Ring infiltrates are common in microbial keratitis and can occur early in the disease, probably as a result of both classical and alternative pathway activation of complement. 59 Providing there is optimal antibiotic therapy a trial of topical steroid treatment may reduce the inflammatory response in persistent ring infiltrates.
Prolonged times for closure of epithelial defects, following the apparent control of replicating bacteria, commonly occur in P.
aeruginosa keratitis. If the clinical signs are improving but the ulcer is not epithelialising after 5 days to a week of adequate therapy con sideration must be given to the toxicity of treat ment, both of the antibiotic or its preservative. Aminoglycosides are amongst the most toxic of the antibiotics to the corneal epithelium60 and both benzalkonium and the mercurials (includ ing thiomersal) have been shown to cause epithelial toxicity. 58 For these reasons we use unpreserved medication where possible.
In patients with pre-existing ocular surface disease any corneal exposure should be cor rected by lid taping or a temporary tarsorraphy.6 1 Therapeutic contact lenses have been recommended in this situation,33 but probably interfere more with corneal metabolism than tarsorraphy and may only be advantageous if protection is required from con junctival keratinisation.
Persistent failure to epithelialise can also be accompanied by stromal degradation often from 1 to 2 weeks or later. If this persists despite the preceding measures a trial of steroid treatment should be considered. The use of conjunctival flaps for the management of this situation has been described.62 Because of possible per sistence of P. aeruginosa for prolonged periods, the reduced corneal levels of antibiotic that are likely to result from the placing of a flap, and our experience of a recurrent infection under a flap, we cannot recommend this.
Perforation results from stromal necrosis and may occur early in untreated infection or late in unsuccessul therapy. If the perforation is less than 1-2mm cyanoacrylate adhesive with or without a scleral patch should be attempted. 63,64 If this fails, or for larger perforations, a thera peutic penetrating keratoplasty is needed after intensive topical, and in this case systemic, therapy for three days to eradicate pseudomonads from the cornea as far as pos sible. Providing all the affected tissue is excised, which may require a corneoscleral graft, this can produce a dramatic improvement but at the cost of a rejection rate of nearly 50% in the first six months.65 , 66 Unlike some others, because of both the risk of recurrent infection and of rejection we do not advocate either lamellar66 or penetrating keratoplasty65 before perforation.
Experimental therapy
Many other treatment modalities have been pro posed for evaluation in experimental models from laser phototherapy,67 topical immuno therapy,68 antibiotic iontophoresis,69 inhibition of elastase26,7 o and cryotherapy. 71 Of these only cryotherapy has been reported in clinical use and may have a role to play in the treatment of P. aeruginosa scleritis. Iontophoresis deserves further evaluation. The inhibition of bacterial proteases during therapy is of doubtful relevance as effective antibiotic treatment will rapidly reduce the numbers of bacteria elaborating the enzymes.
However, immunisation of compromised patients to give high antibody titres to pilin antigen to reduce adherence, to somatic and flagella antigens to enhance opsonisation, or to the proteases to prevent early corneal destruction may be evaluated in the future as prophylaxis. 
